In a recent publication in the Journal of Medicinal Chemistry, a collaborative research led by the scientist Dr. H. Day, in conjunction with a consortium of researchers, explored the development of allosteric inhibitors targeting SH2 domain-containing protein tyrosine phosphatase-2 (SHP2) for cancer therapy.
ReadyCell is attending BIO-Europe Spring in Barcelona. The event is expected to bring together executives from biotech and pharma companies.
With this infographic, we proudly show the key facts we have achieved in recent times in promoting gender equality and women’s rights in the company.
The article highlights the discovery of a series of azetidine derivatives, known as BGAz compounds, that exhibit potent bactericidal activity against both drug-sensitive Mycobacterium tuberculosis and multidrug-resistant TB strains.
In honor of the International Day of Women and Girls in Science, we present a series of videos featuring insights from our team members that explore the diverse experiences and perspectives of the talented women at ReadyCell.
